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The specificity of the retroviral protease is deter-
mined by the ability of substrate amino acid side chains
to bind into eight individual subsites within the enzyme.
Although the subsites are able to act somewhat inde-
pendently in selection of amino acid side chains that fit
into each pocket, significant interactions exist between
individual subsites that substantially limit the number
of cleavable amino acid sequences. The substrate pep-
tide binds within the enzyme in an extended anti-paral-
lel b sheet conformation with substrate amino acid side
chains adjacent in the linear sequence extending in op-
posite directions in the enzyme-substrate complex.
From this geometry, we have defined both cis and trans
steric interactions, which have been characterized by a
steady state kinetic analysis of human immunodefi-
ciency virus, type-1 protease using a series of peptide
substrates that are derivatives of the avian leukosis/
sarcoma virus nucleocapsid-protease cleavage site.
These peptides contain both single and double amino
acid substitutions in seven positions of the minimum
length substrate required by the retroviral protease for
specific and efficient cleavage. Steady state kinetic data
from the single amino acid substituted peptides were
used to predict effects on protease-catalyzed cleavage of
corresponding double substituted peptide substrates.
The calculated Gibbs’ free energy changes were com-
pared with actual experimental values in order to deter-
mine how the fit of a substrate amino acid in one subsite
influences the fit of amino acids in adjacent subsites.
Analysis of these data shows that substrate specificity is
limited by steric interactions between pairs of enzyme
subsites. Moreover, certain enzyme subsites are rela-
tively tolerant of substitutions in the substrate and ex-
ert little effect on adjacent subsites, whereas others are
more restrictive and have marked influence on adjacent
cis and trans subsites.
The retrovirus protease (PR)1 is responsible for the post-
translational processing of viral gag and gag-pol polyprotein
precursors (1). This proteolytic processing is a necessary step in
the replication of infectious virus and is a late event occurring
as particles bud from infected cells. Cleavage of the viral
polyproteins requires human immunodeficiency virus, type 1
(HIV-1), or avian myeloblastosis/Rous sarcoma virus (AMV/
RSV) PR to act on nine unique sequences, each 8 amino acids in
length. Consistent with this is the finding that the minimum
length of a peptide substrate required for specific cleavage by
either PR is 6–8 amino acids, depending upon the source of the
enzyme (2–4). Substrates bind to HIV-1 PR in an extended
anti-parallel b strand conformation with substrate amino acid
side chains adjacent in the linear sequence extending in oppo-
site directions in the enzyme-substrate complex (see Fig. 1).
Interaction between substrate amino acid side chains and the
corresponding binding pockets in the enzyme determines en-
zyme specificity. It has been shown previously that a variety of
amino acid residues can be accommodated in each of the en-
zyme subsites, when single amino acid substitutions are placed
in the context of an efficiently cleaved substrate (5). Addition-
ally, it was found that individual enzyme subsites are capable
of acting relatively independently in recognition of amino acids
in the corresponding substrate position (6). If each of the eight
subsites were able to accept n different amino acid side chains,
where n 5 4–7 amino acids as found in the naturally occurring
gag and pol polyprotein cleavage sites and the subsites were
acting completely independently in substrate amino acid selec-
tion, then PR would be able to cleave n8 different substrate
sequences. However, in contrast to cellular proteases such as
pepsin (7), the retroviral PR displays a remarkably limited
substrate range, cleaving only a very select set of amino acid
sequences.
In this report, we define substrate parameters that limit the
possible combinations of amino acids that constitute a func-
tional cleavage site. The activity of HIV-1 PR was analyzed
with the use of a library of single and double substituted
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synthetic peptide substrates, representing the cleavage junc-
tion between the naturally occurring RSV nucleocapsid (NC)
and PR proteins in the gag precursor polypeptide. A steady
state kinetic analysis was used to calculate DDG values repre-
senting the difference in the Gibbs’ free energy changes for the
proteolysis reactions resulting from amino acid substitutions in
the wild type NC-PR-based substrate. A comparison was made
between the experimentally observed DDG values for the dou-
bled substituted peptides and the predicted DDG values calcu-
lated using the data derived from the single substituted pep-
tides. This analysis indicates that there are steric interactions
between amino acids in adjacent and alternate substrate posi-
tions that restrict the combinations of amino acids that com-
prise a functional cleavage site.
EXPERIMENTAL PROCEDURES
Purification of Retroviral Proteases—AMV PR was purified from
virus obtained from Molecular Genetic Resources, Tampa, FL as de-
scribed previously (11). HIV-1 PR was expressed in Escherichia coli and
purified from the inclusion body fraction according to a procedure
developed by Dr. C. Z. Giam, Case Western Reserve University.2
Briefly, E. coli JM105 harboring a plasmid with a lacZ-HIV-1 PR fusion
protein under control of the lac promotor was expressed with the addi-
tion of isopropyl-1-thio-b-D-galactopyranoside (2 mM) for 10 h. The
inclusion body fraction was isolated and solubilized with 8 M urea and
150 mM 2-mercaptoethanol. The denatured protein was passed over a
DEAE-Sephadex column equilibrated with 8 M urea, 150 mM 2-mercap-
toethanol, 20 mM Tris-HCl, pH 8.8. The denatured fusion protein did
not bind to the column. The protein was renatured by removal of the
urea by dialysis against 20 mM HEPES, pH 7.0, 10 mM 2-mercaptoeth-
anol. This activates the PR to cleave itself out of the fusion protein. The
PR preparation was then dialyzed against 20 mM MES, pH 5.5, 10 mM
mercaptoethanol and uncleaved fusion protein was separated from PR
by passing through a carboxylmethyl-cellulose column equilibrated
with 20 mM MES, pH 5.5, 0.1 M KCl, and 10 mM mercaptoethanol.
Protease was eluted from column by running a linear gradient from 0.1
to 1 M KCl with 20 mM MES, pH 5.5, and 10 mM 2-mercaptoethanol.
Protease eluted at about 0.3 M KCl. The purified PR was concentrated
with an amicon centrifuge concentrator to 0.2 mg/ml and frozen in
aliquots at 280 °C. Aliquots of HIV-1 PR were used only once. The
HIV-1 PR was greater than 95% pure as judged by SDS-polyacrylamide
gel electrophoresis. The preparations specifically cleaved peptide sub-
strates based on the natural polyprotein cleavage sites and had no
detectable cleavage on nonrelated protein sequences or mature HIV-1
reverse transcriptase.
Peptides—The peptides used in this study were synthesized chemi-
cally and purified as described previously (8). The peptides were ana-
logs of the RSV NC-PR cleavage junction. The natural sequence is
indicated in bold letters, and the substituted substrates contained ei-
ther one or two amino acid changes in the underlined positions of this
sequence: PPAVS-LAMTMRR. Peptides were solubilized in 1 mM
2-mercaptoethanol or 1 mM dithioerythritol, and their concentrations
were determined by amino acid composition analysis.
Assay of PR Activity—The reaction mixture contained 80 mM sodium
phosphate, pH 5.9, 0.8 M sodium chloride, 10–400 mM peptide as indi-
cated, and 0.5 - 5 mg/ml HIV-1 PR. Reaction volumes were 25 ml.
Incubations times varied from 2 to 10 min at 37 °C depending upon the
substrate. Reactions were initiated by the addition of PR and stopped by
the addition of 300 ml of 0.5 M sodium borate, pH 8.5. 20 ml of 0.05%
(w/v) fluorescamine was then added. HIV-1 PR was never incubated
more than 10 min due to its instability, presumably a result of auto-
degradation. After reaction with fluorescamine, the relative fluores-
cence was determined on a Perkin-Elmer LS-50B spectrofluorometer
using an excitation wavelength of 386 nm and an emission wavelength
of 477 nm. Excitation and emission slit widths were 5 and 10 nm,
respectively. Relative fluorescence intensity was converted to nmoles of
product using a standard curve described by the following equation:
nmol of product 5 relative fluorescence intensity/400. The standard
curve was obtained using a hexapeptide with a free amino terminus (5).
The AMV PR was assayed as described previously (5). The peptides
used in this study were designed with prolines at their amino termini so
that the relative fluorescence intensity represents only the newly
formed amino termini produced as a result of proteolytic cleavage.
Arginine residues were added to the carboxyl terminus to improve
solubility of the peptides, without changing their kinetic parameters.
Steady State Kinetic Analysis—Kinetic constants were determined
using the assay described above. Concentrations of peptide ranged from
0.25 to 4 times the Km value. No more than 20% of the substrate was
allowed to be consumed during the course of any given experiment.
Initial velocity data used to calculate kinetic constants were obtained
from at least three experiments performed in duplicate. Kinetic con-
stants were determined by a nonlinear fit of the data to the Michaelis-
Menten equation using the NFIT program (9, 10). Correlation coeffi-
cients of the fit were greater than 0.98, and the standard deviation of
the constants reported was , 20%.
DDG Calculations—The DDG values for single and double substi-
tuted peptides were determined from steady state kinetic data (kcat/Km
values) by the relationships described below. The equations were de-
rived from relationships described by Fersht (12). DDGx or DDGy repre-
sent the deviation in the Gibbs’ free energy change from the wild type
NC-PR peptide for single substituted peptides. DDGxy represents devi-
ation in the Gibbs’ free energy for a double substituted peptide. The
DDGxy was determined experimentally and also predicted mathemati-
cally by adding the DDG values from the corresponding single substi-
tuted peptides.
DDGxy 5 DDGx 1 DDGy ~predicted! (Eq. 1)
where
DDGxy 5 2 RTln@$kcat/Km}xy/$kcat/Km%o# ~experimental!
(Eq. 2)
DDGx 5 2 RTln@$kcat/Km}x/$kcat/Km%o# (Eq. 3)
DDGy 5 2 RTln@$kcat/Km%y/$kcat/Km%o# (Eq. 4)
{kcat/Km}o represents the catalytic efficiency for the wild type
NC-PR peptide; {kcat/Km}x and {kcat/Km}y represent the catalytic
efficiency for different single substituted peptides, respectively;
{kcat/Km}xy represent the catalytic efficiency for double substi-
tuted peptides.
Molecular Modeling—The starting structure consisted of the prote-
ase dimer from the crystal structure of HIV-1 protease with the inhib-
itor, JG365, (13), and a model for a peptide substrate. The structures
were examined on a Silcon Graphics SGI316 computer graphics system
running the program CHAIN (14). The peptide substrate was built by
altering amino acid side chains in the inhibitor and forming a peptide
group (CONH) instead of the nonhydrolyzable bond of the inhibitor. The
modeled substrate consists of variations of the central eight residues
(P4-P49), Pro-Ala-Val-Ser-Leu-Ala-Met-Thr, of the peptide representing
the NC-PR cleavage site of RSV, where the peptide bond between Ser
and Leu is hydrolyzed. All the crystallographic water molecules were
included because several appeared to be structurally important. A
transition state substrate model was built in which the scissile peptide
CO-NH was replaced by the transition state C(OH)2-NH2, and the
water that interacts with either the substrate or inhibitor and with the
flaps of the protease was removed.
The atomic coordinates for the substituted residues were produced
with the program AMMP (15), and the energy of the HIV protease-
substrate complex was minimized. A modified version of the UFF po-
tential set (16) was used. Infrared spectral data were not included in the
original UFF parameterization and have been used to improve the
parameters for proteins and nucleic acids.3 These modifications do not
significantly change the performance of the potential set on small
molecules but result in consistently smaller root mean square devia-
tions between minimized and observed protein and nucleic acid struc-
tures. One of the strengths of the UFF potential is that the new terms
were easy to add in a manner that is consistent with the rest of the
potential set. The atomic charges from the AMBER all atom set were
used for the protein and water (18). Charges for the nonstandard groups
in the transition state were produced as described in Harrison et al.
(19).
No screening dielectric term or bulk solvent correction was included.
No cut-off was applied for nonbonded and electrostatic terms, which
were calculated with an algorithm that amortizes or spreads the cost of
calculation over many simpler calculations, which results in lower
2 C. Z. Giam, personal communication. 3 I. T. Weber, and R. W. Harrison, submitted for publication.
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average cost, as described in Harrison and Weber (20). The atomic
positions for the protein and water molecules were initially tethered to
those in the crystal structure of HIV-1 protease in order to calculate and
minimize the hydrogen atom positions. The side chain atoms were
removed down to the Cb atom, or the Ca for substitution of Gly, for the
substituted amino acids, and the new atomic positions were created by
a variation on distance geometry (19). The new atoms were minimized
with respect to bond, angle, torsion, and hybrid potentials. The protease
structure with nonhydrogen atoms from the crystal structure and min-
imized hydrogen atoms was combined with each of the different pep-
tides with single or double amino acid substitutions. Then, each of the
side chain torsion angles for substituted residues in the peptide sub-
strate was rotated through 360 ° in steps of 15 ° to search for alternate
conformations. This torsion search finds the angle(s) that have a min-
imum in the nonbonded energy. Finally, each model of HIV protease
with a different substrate was optimized by a longer minimization
using 100 steps of conjugate gradients followed by eight cycles of alter-
nating conjugate gradients (30 steps) and short runs of molecular dy-
namics (20 fs steps at 300 K).
RESULTS AND DISCUSSION
We have used a simple method to determine the extent to
which amino acids in given substrate positions influence the fit
of adjacent and alternate substrate amino acids into their
corresponding enzyme subsites. This method involves a steady
state kinetic analysis of HIV-1 PR on a series of peptide sub-
strates based on the RSV NC-PR cleavage sequence that have
two residues altered from wild type. The amino acid substitu-
tions chosen were those that were analyzed as single substitu-
tion mutations (Ref. 5 and in Table I) and were designed to test
primarily steric effects of the side chains in the substituted
pairs. Steady state data from the single and double substituted
peptides were used to calculate DDG values according to the
equations listed under “Experimental Procedures.” Binding of
substrate peptides to HIV PR has been deduced from exami-
nation of crystal structures of HIV PR complexed with various
peptide-like inhibitors (21). Inhibitors and by analogy sub-
strates bind in an extended anti-parallel b sheet conformation
between the flaps and the active site. This is shown in Fig. 1,
which presents the NC-PR peptide substrate docked in the
eight subsites of a retrovirus PR. Because of this structural
orientation, amino acid side chains in adjacent substrate posi-
tions, such as P1 and P2, extend in an opposite or trans con-
figuration; amino acid side chains in every other position, such
as P1 and P3, extend in the same or cis configuration. In cases
where amino acids in given substrate positions have little in-
fluence on the fit of amino acids in adjacent or alternate posi-
tions, DDG values determined for the double substituted pep-
tide should equal the sum of the DDG values determined for the
single substituted peptides (Equation 1). In contrast, if inter-
actions between the tested amino acids in the substrate are
important, there will be discrepancies between the experimen-
tal and predicted DDGxy values.
Steady state kinetic parameters for a series of single and
double substituted NC-PR peptide substrates with HIV-1 PR
are presented in Tables I and II, respectively. The RSV NC-PR
peptide was chosen as a reference substrate because it is
cleaved efficiently by both the HIV-1 and AMV PRs and be-
cause it contains many small amino acid residues that present
little or no steric interference to the other substrate positions.
The kcat and Km are presented as values relative to the wild
type NC-PR peptide. In Table II, double substitutions in P1-P3
and P2-P19 examine cis interactions, whereas double substitu-
tions in P3-P2, P2-P1, and P1-P19 examine trans interactions.
A more limited data set for the AMV PR acting on selected
peptides is presented in Table III.
cis Interactions—The HIV-1 PR data from Table II were
plotted in Figs. 2 and 3, with each examining a different set of
potential interactions between substrate positions. Fig. 2A dis-
plays the data for simultaneous substitutions in P3 and P1
where the side chains of the substrate amino acids extend in
the same or cis direction. This plot presents the predicted and
experimentally observed DDG values for each of the substituted
pairs. The lower the DDG value, the more efficiently the sub-
strate is cleaved. A DDG value of zero means that the substi-
tuted peptide is cleaved at the same rate as the wild type
NC-PR substrate. When Arg is fixed in P3 and Gly or Ala is
placed in P1, the predicted and experimental DDG values are
very similar. This indicates that there is little interaction be-
tween these substituted amino acid pairs. In contrast, when
larger side chains, such as in Leu or Trp, are placed in P1, the
experimentally determined DDG values are considerably more
positive than the predicted DDG values by as much as 2.5
kcal/mol. This represents a rate of cleavage that is approxi-
mately 30-fold lower than expected from the single substituted
peptide substrates. Similar activity data are obtained if a large
residue such as Trp is fixed in P1 and various sized residues are
placed in P3. The relatively small Ser or Thr is accommodated
in P3 where the predicted and experimentally determined DDG
values agree. However, when the larger His or Arg residues are
placed in P3, the peptides are significantly poorer substrates
than predicted from the single substituted peptide data.
We propose that this lower activity is the result of steric
interference that places one or both of the amino acids in the cis
subsites in an altered conformation not favorable for binding
and cleavage. This is suggested by analysis of the peptide
substrates modeled in the HIV-1 PR structure in Fig. 4, which
TABLE I
Comparison of HIV-1 PR kinetic data for AMV/RSV NC-PR substrates with single substitutions in the P3 to P19 positions
Varying concentrations of the NC-PR (PPAVS-LAMTMRR) or NC-PR substrates with amino acid substitutions in the P3 to P19 positions as
indicated were incubated with purified HIV-1 PR (50 ng), and the extent of cleavage was determined using the fluorescamine assay described under
“Experimental Procedures.” The wild type amino acid in the NC-PR peptide is indicated in parentheses in the first column.
Substrate position Substituted amino acid kcat
a Km Relative kcat/Km DDGxory observed
b
min21 mM mM21 min21
P3 (Ala) Phe 1.8 0.9 2.1 20.45
Ser 1.2 1.3 0.92 0.05
Thr 0.87 1.3 0.7 0.22
P2 (Val) Ala 1.1 4.3 0.3 0.8
His 0.9 3.8 0.25 0.85
P1 (Ser) Ile 1.9 1.2 1.6 20.29
Val 1.4 2.3 0.62 0.29
P19 (Leu) Ala 0.008 3.03
Val 0.7 6.6 0.1 1.42
a The kinetic parameters for the P3 to P19-substituted NC-PR substrates are given relative to the unmodified wild type substrate, which is
defined as equal to 1 in each case. For HIV-1 PR, the Km varied from 13.4 to 16 mM, and kcat varied from 14.9 to 43.8 min
21, with calculated kcat/Km
values from 1.1 to 2.7 min21 mM21 dependent upon the enzyme preparation used.
b The DDG values were calculated from the kinetic data as described under “Experimental Procedures.”
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shows the relative positions of the P3 to P1 amino acids of the
NC-PR peptide substrate predicted by energy minimalization.
Shown are two peptides, both of which have His substituted for
Ala in P3 and one that also has Trp substituted for Ser in P1
(Fig. 4, thin lines and balls). The bulky Trp in P1 appears to
directly effect the position of the His in P3, which is pushed
back toward Phe53. The only exception to this steric argument
observed so far involves Gly in P3 with Trp in P1. Glycine,
which does not have a side chain to contribute to substrate
binding energy, is a special case and will be discussed later in
the context of several Gly substituted peptides.
A similar steric interaction can be seen with cis substitutions
in P2 and P19 (Fig. 2B). When Gly or Ala is placed in P2 with
Phe in P19, the predicted and experimental values agree. When
the larger Leu is placed in P2, there appears to be insufficient
flexibility in the binding pockets to accommodate the combina-
tion of the two large groups extending into the same side of the
enzyme. Peptides that fixed Leu in P2 and vary the amino acid
in P19 also have been analyzed. However, these peptides, which
have Ala or Gly in P19, were predicted to be cleaved poorly
because the single substituted substrates are cleaved with low
efficiency. Indeed, this was observed, and experimental DDG
values could not be calculated accurately because product did
not accumulate to any measurable extent under the assay
conditions used. In the above argument, the size of an amino
acid relative to its given subsite determines the magnitude of
the steric effect. For instance, Leu would be considered a large
residue in the small S2 subsite, although it would be a medium
sized residue in the larger S1 or S3 subsites (see Fig. 1) (2).
In the data shown in Fig. 2B, it was surprising to find that
the presence of His in P2 and Phe in P19 are predictive. This is
in contrast with what was observed when His was in P3 and
Trp in P1 (Fig. 2A). The disparity between these two results
may reflect differences between subsites that interact with
substrate amino acids that span across the scissile bond and
those that do not. Each half of the inhibitor forms a short b
sheet with the two anti-parallel strands of the flap and residues
27–29 of one subunit (22, 23, 24) (Fig. 5). There is a set of
hydrogen bond interactions between the carbonyl oxygens and
amides of the inhibitor and the main chain carbonyl oxygens
and amides of PR. The b sheets are interrupted near the
nonhydrolyzable group of the inhibitors, where there is a kink
in the extended conformation of the inhibitor. The interruption
in the b sheet near the scissile bond means that the P2-P19 side
chain interactions are not the same as those of P1-P3 or P19-
P39. In fact, the side chains of P1 and P19 tend to be directed
away from each other so that P1 interacts more closely with P3
than P19 with P2. Therefore, steric interactions involving P1 and
P3 may be more pronounced than those involving P19 and P2.
trans Interactions—Although steric relationships between
adjacent cis subsites were expected, it was not clear whether
such relationships would also be present for adjacent trans
subsites. To examine potential trans interactions, we extended
the double substituted peptide study to include substitutions of
amino acids adjacent in the linear substrate sequence. The
results of substitutions made in P3 and P2 are summarized in
Fig. 3A. In contrast to what is observed with the cis interaction
data (Fig. 2, A and B), there does not appear to be a significant
steric influence with any of these tested substituted substrates
(Fig. 3A). The predicted and experimental DDG values were in
close agreement over the entire range of substitutions includ-
ing the presence of two large residues, Arg in P3 with Leu in
P2. Leu in P2 is a strong determinant limiting the amino acids
that can be accommodated in P1 or P19.
FIG. 1. Schematic representation of the AMV/RSV NC-PR substrate, PAVSLAMT, from P4 to P4* in the S4 to S4* subsites of PR. The
relative size of each subsite is illustrated by the area enclosed by the curved line around each substrate side chain. Protease residues forming the
subsites are shown for those that differ between the AMV/RSV and HIV-1 PRs. The AMV/RSV PR residue is shown outside of the parentheses, and
the HIV-1 PR residue is shown in the parentheses. Most of the residues contribute to more than one adjacent subsite, and this is indicated by the
position of the label relative to the subsites.
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Although there appear to be limited interactions between
amino acids in P3 and P2, there are significant interactions
observed when similar substitutions are placed in the P2 and
P1 trans positions. With Trp fixed in P1, Ala substituted for the
natural Val in P2 was predictive, whereas the substitution of
the larger His or Leu was not (Fig. 3B). The mechanism by
which amino acids in the trans configuration interact is not
clear. However, it is likely that the presence of a large sub-
strate amino acid in an enzyme subsite will distort the position
of the substrate peptide backbone in a way that can be cata-
lytically compensated for by placing a smaller rather than a
larger residue in the trans subsite. This can be seen in the
structural model shown in Fig. 6. Shown are two peptides in
which Leu has been substituted in P2. One of the two peptides
also has Trp substituted for Ser in P1. The presence of the Trp
in P1 results in substantial movement of the substrate peptide
backbone with Leu in P2 being pushed deeper into the S2
subsite resulting in loss of activity. A similar a carbon back-
bone distortion could also contribute to the differences in the
DDG values observed with the cis substituted peptides.
Trp in P1 and His or Leu in P2 represent about the largest
residues that can fit into S1 and S2, respectively, without
substantial loss of catalytic efficiency (5). To determine
whether steric interactions occur between other trans sub-
strate pairs, substitutions were also placed in the P1 and P19
positions (Fig. 3C). In these instances, both favorable and un-
favorable steric interactions were observed. With Trp or Leu
fixed in P1, the presence of Ala in P19 produced a substrate that
was more active than predicted. In contrast, the placement of
the medium sized Val in P19 produced a substrate that was as
TABLE II
Comparison of HIV-1 PR kinetic data for AMV/RSV NC-PR substrates with double substitutions in the P4 to P19 positions
Varying concentrations of the NC-PR (PPAVS-LAMTMRR) or NC-PR substrates with double amino acid substitutions in the P4 to P19 positions
as indicated were incubated with purified HIV-1 PR (50 ng), and the extent of cleavage was determined using the fluorescamine assay described
under “Experimental Procedures.” The wild type amino acid in the NC-PR peptide is indicated in parentheses in the first column.
Substrate positions Substituted aminoacids kcat
a Km Relative kcat/Km DDGxy predicted DDGxy observed
b
min21 mM mM21 min21
P4 (Pro) P1 (Ser) Gly Trp 9.4 3.8 2.5 21.07 20.58
P3 (Ala) P2 (Val) Arg Gly 0.6 2.7 0.22 0.024 0.99
Arg His 0.6 3.4 0.18 0.56 0.99
Arg Ala 1.5 5.9 0.3 0.51 0.8
Arg Leu 1.5 1.0 1.5 20.4 20.27
Gly Leu 2.4 1.3 1.9 20.11 20.4
P3 (Ala) P1 (Ser) Arg Gly 0.2 0.6 0.42 0.02 0.54
Arg Leu 8.9 18.4 0.5 21.79 0.45
Arg Ala 7.1 2.2 3.2 20.54 20.73
Arg Trp 0.9 3.5 0.3 21.58 0.74
His Trp 1.5 3.4 0.4 21.15 0.56
Gly Trp 1.3 1.3 1.0 21.29 0
Ser Trp 7.5 0.97 7.73 21.24 21.26
Thr Trp 4.9 1.2 4.1 21.07 20.87
P2 (Val) P1 (Ser) His Trp 0.5 1.6 0.3 20.44 0.74
Leu Trp 0.2 2.6 0.08 21.4 1.56
Gly Trp 0.4 2.3 0.2 20.97 0.99
Ala Trp 5.0 1.9 2.45 20.05 20.55
P2 (Val) P19 (Leu) His Phe 0.9 3.9 0.2 1.07 0.84
Gly Phe 0.9 4.1 0.22 0.53 0.99
Leu Phe 1.0 37.6 0.03 0.11 2.16
Ala Phe 2.2 5.9 0.4 1.0 0.62
P1 (Ser) P19 (Leu) Trp Phe 0.2 3.1 0.06 21.07 1.73
Trp Gly 0.02 1.9 0.01 2.5 2.8
Trp Ala 1.5 5.7 0.3 1.74 0.8
Trp Val 1.3 1.79 0.73 0.13 0.19
Leu Ala 3.4 14.8 0.3 1.52 0.8
Leu Phe 3.1 45.6 0.07 21.28 1.6
Leu Gly 0.05 5.2 0.01 2.3 2.8
Ile Phe 0.97 5.7 0.17 20.07 1.09
a The kinetic parameters for the P4 to P19-substituted NC-PR substrates are given relative to the unmodified wild type substrate, which is
defined as equal to 1 in each case. For HIV-1 PR, the Km is 16 mM, kcat is 43.8 min
21, and the calculated kcat/Km value is 2.7 min
21 mM21.
b The DDG values were calculated from the kinetic data as described under “Experimental Procedures.”
TABLE III
Comparison of AMV PR kinetic data for AMV/RSV NC-PR substrates with single and double substitutions in the P3 to P19 positions
Varying concentrations of the NC-PR (PPAVS-LAMTMRR) or NC-PR substrates with amino acid substitutions in the P3 to P19 positions as
indicated were incubated with purified AMV PR (6–24 ng), and the extent of cleavage was determined using the fluorescamine assay described
under “Experimental Procedures.” The wild type amino acid in the NC-PR peptide is indicated in parentheses in the first column.
Substrate position Substituted aminoacid kcat
a Km Relative kcat/Km DDGxy predicted DDGxy observed
b
min21 mM mM21 min21
P3 (Ala) P1 (Ser) Arg Gly 0.59 0.18 0.3 0.41 0.74
Arg Leu 1.3 7.1 5.5 22.31 21.05
Arg Trp 1.1 4.0 3.6 20.02 1.26
Phe Trp 4.5 2.5 0.6 23.24 0.31
Gly Trp 0.57 4.1 7.2 21.37 21.2
a The kinetic parameters for the P4 to P19 substituted NC-PR substrates are given relative to the unmodified wild type substrate, which is
defined as equal to 1 in each case. For AMV PR, the Km is 47 mM, kcat is 21.6 min
21, and the calculated kcat/Km value is 0.45 min
21 mM21.
b The DDG values were calculated from the kinetic data as described under “Experimental Procedures.”
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active as predicted, whereas the placement of a larger Phe in
P19 resulted in an efficiency of cleavage that was considerably
less than predicted. Similar results are obtained if the bulky
group is fixed in P19 and the size of the residue in P1 is varied
(Fig. 3C).
As mentioned above, we have detected only two of the pep-
tides so far that were more active than predicted by the single
substituted peptides. These are the P1 Trp-P19 Ala and the P1
Leu-P19 Ala peptides. These peptides were predicted to be poor
substrates primarily because single P19 Ala substituted pep-
tides are cleaved poorly. The presence of a larger Leu or Trp
substituted for Ser in P1, however, seems to restore cleavage of
the P19 Ala substituted substrates to levels similar to those
observed with the unmodified reference peptide (Fig. 3C). The
P19 position has a preference for a large hydrophobic amino
acid side chain. Therefore, an Ala residue in this position is too
small to fit well into the HIV-1 PR S19 subsite to form the
requisite stabilizing van der Waals’ interactions with subsite
amino acids. The presence of a bulky group in P1 may position
the P19 Ala deeper into the S19 subsite allowing it form van der
Walls interactions and thereby producing a substrate with
more activity than predicted by the single substituted peptides.
This interpretation is consistent with the observation that dou-
ble substituted peptides containing Gly in P19 and Trp or Leu
in P1 are also poor substrates. However, in this instance, an
adjacent Trp or Leu in P1 does not “rescue” the cleavage defect.
A Gly residue cannot provide a side chain for van der Walls
interactions, even if the backbone of the peptide is shifted due
to the larger residue in P1. Restoration of cleavage of a peptide
containing Ala in P19 is predicted to be stronger when a bulky
group is in a trans rather than the cis configuration. This is
what is observed as shown in Fig. 2B. When Leu is placed into
the adjacent cis position, as in the P2 Leu-P19 Ala peptide,
there is very little cleavage of this peptide detected. Of the
FIG. 2. Comparison of experimental and predicted DDG values for cleavage by HIV-1 PR of the RSV NC-PR peptide substrates
containing double amino acid substitutions in the cis orientation. The calculated and experimentally determined DDG values listed in
Table II for cleavage of a peptide substrate representing the RSV NC-PR cleavage site with the sequence of PAVS-LAMTMRR but containing
substitutions in the P3 and P1 positions (A) and P2 and P19 (B) were plotted as a function of the amino acids substituted (at the top of the graphs).
A DDG value equal to zero indicates that a substituted peptide substrate has an activity equal to the wild type NC-PR peptide substrate. Positive
DDG values reflect substrates that are less efficiently cleaved, and negative DDG values reflect substrates cleaved more efficiently than the wild
type substrate. E, predicted DDG values; Ç, observed DDG values.
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FIG. 3. Comparison of experimental
and predicted DDG values for cleav-
age by HIV-1 PR of the RSV NC-PR
peptide substrates containing double
amino acid substitutions in the trans
orientation. The calculated and experi-
mentally determined DDG values listed in
Table II for cleavage of a peptide sub-
strate representing the RSV NC-PR but
containing substitutions in P3 and P2 (A),
P2 and P1 (B), and P1 and P19 (C) were
plotted as a function of the amino acids
substituted (top of panels) as described in
the legend to Fig. 2. E, predicted DDG
values; Ç, observed DDG values.
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three trans interactions examined, P3-P2, P2-P1, and P1-P19,
the two involving exclusively the S1, S19, or S2 subsite showed
interaction effects, whereas the pair involving S3 and S2 did
not. This may reflect the fact that S2, S1, and S19 are internal
subsites near the scissile bond, whereas S3 is found near the
enzyme surface and therefore able to accommodate a variety of
larger amino acids with little steric interaction with the adja-
cent subsite.
Glycine Substitutions in Peptides—In this study, we have
examined 10 double substituted peptides with a Gly substi-
tuted in one of the substrate positions. Of these, seven were
reasonably predictive and three were not. These data include a
P4 substituted Gly with Trp in P1 and Gly substituted in P3,
P2, or P19 positions (Table II). The effect of substitution of a Gly
residue into a peptide substrate is complicated by the potential
loss of a side chain that could form van der Waals interactions
with key amino acids in each of the subsites. The data suggest
that enzyme subsites unoccupied by substrate side chains may
be more sensitive to substitutions in adjacent subsites. Nor-
mally, an occupied subsite filled with a side chain could be
“buffered” from perturbations in structure by stabilizing van
der Waals’ interactions between the side chain and the enzyme
subsite. This would not be the case with an empty subsite. Thus
the single Gly substituted peptides may not be as predictive of
the activity on the corresponding double substituted peptides
as are single substituted peptides containing side chains that
contribute to the binding.
Other Considerations—Substrate steric relationships also
apply to the AMV PR. In this case, we have analyzed a small
number of double substituted peptides. These data are pre-
sented in Table III for P3 and P1 substituted peptides. There
are large discrepancies between the predicted and experimen-
tally determined DDG values when large residues are substi-
tuted in P3 and P1. Moreover, the larger the size of the substi-
tuted residues, the larger the discrepancy in the DDG values.
For instance, there is a 0.33 and 1.28 kcal/mol discrepancy for
the peptide with Arg in P3 and Gly or Trp, respectively, in P1.
When Phe is placed in P3 with the Trp in P1, the discrepancy
FIG. 4. Stereo views of the NC-PR peptide containing substitutions at P3 and P1 is shown in the PR binding site. Residues P3-P1
of the substrate with Trp at P1 and His at P3 are shown in a ball and stick representation (thick lines) compared with the single substituted
substrate with His at P3 and Ser at P1 (thin lines). PR residues 819 to 849 that form the top of subsites S1 and S3, Phe53, which lies to one side
of the S3 subsite, and V32, which forms the bottom of the subsite S2, are shown as thin lines. Trp at P1 displaces His at P3 from its position in
the single substituted peptide. The atomic coordinates were obtained by molecular modeling as described under “Experimental Procedures.” Each
of the substituted residues was positioned in a minimum energy conformation by rotating the side chain torsion angles, except for Gly and Ala.
Then the HIV protease-substrate models were minimized to ensure good bond and angle geometry and to remove any close contacts between atoms
by adjusting the atomic positions. The minimized models showed that protease main chain atoms had root mean square differences of 0.41–0.43
Å compared with the starting HIV protease crystal structure. This is well within the range of 0.16–0.79 Å for root mean square differences between
different crystal structures of the same protein (24, 25).
FIG. 5. Stereo views of interactions of a peptide inhibitor with HIV-1 PR. The inhibitor and PR are from the crystal structure of Jaskolski
et al. (17). The main chain atoms of the inhibitor and residues 46–55 and 25–29 of each subunit in the PR dimer are shown. The side chain atoms
of the two catalytic aspartic acid residues are also indicated. Each half of the inhibitor forms a series of b sheet-like hydrogen bond interactions
with PR residues 27–29 near the catalytic aspartates and with the two anti-parallel b strands of the flap of each subunit. In the center, these
interactions are interrupted near the nonhydrolyzable group of the inhibitor, and interactions are formed with a conserved water molecule.
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increases to 2.9 kcal/mol.
Of the double substituted peptide set analyzed in this study,
about half had experimentally determined DDG values that
were predicted well from the single substituted data. These
peptides involve substitutions of at least one small sized resi-
due relative to a given subsite in one of the two substituted
substrate positions. In contrast, about 45% of the double sub-
stituted peptides were cleaved with catalytic efficiencies that
were significantly worse than predicted. These discrepancies
can be explained by steric interference. Only two of the pep-
tides tested so far had more activity than predicted. Thus,
substitutions of various amino acids into the different sub-
strate positions limit the number of amino acid combinations
that constitute a cleavable site. Although the data set analyzed
in this report has focused primarily on nonprime substrate
positions, we predict that similar relationships probably exist
for the prime side (see Fig. 1). Also, there may be effects of
substitutions of amino acid residues at substrate positions 3 or
4 amino acids apart in the linear sequence, on both sides of the
scissile bond, that would restrict further the choice of amino
acids that would constitute a cleavage site. These latter inter-
actions, if they are important, may be of less magnitude than
those involved in adjacent and alternate subsites reported in
this study. Taken together, these results indicate that although
many different side chains can bind effectively into each en-
zyme subsite, enzyme specificity is limited by interactions be-
tween substrate amino acids bound in both cis and trans posi-
tions. Interactions between at least one pair of subsites
examined appears to be minimal. Clearly, an understanding of
these relationships will be very important to the rational de-
sign of HIV-1 PR inhibitors as potential therapeutic agents for
AIDS. For a potential compound to bind effectively in the
enzyme subsites, it must not violate any of the adjacent occu-
pancy rules defined in this study.
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FIG. 6. Stereo views of the NC-PR
peptide containing substitutions at
P2 and P1 is shown in the PR binding
site. Residues P3-P1 of the substrate with
Trp at P1 and Leu at P2 are shown in a
ball and stick representation (thick lines)
compared with the single substituted sub-
strate with Leu at P2 and Ser at P1 (thin
lines) as described in the legend to Fig. 4.
PR residues 819 to 849, which form the top
of subsites S1 and S3, Phe53, which lies to
one side of the S3 subsite, and V32, which
forms the bottom of subsite S2, are shown
as thin lines. Trp at P1 displaces Leu at
P2 and Ala at P3 from their positions with
Leu at P2 in the single substituted pep-
tide. In the double substitution, P2 Leu is
moved deeper into the S2 subsite.
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